uniQure (QURE) announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, CEO of uniQure, and will be based in the Company’s Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab’s appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He will continue to lead all research, non-clinical research, and vector and enabling technology. Dr. Abi-Saab joins uniQure from the Belgium-based biopharmaceutical company Galapagos (GLPG), where he served as Chief Medical Officer from 2017 through 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on QURE:
- uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
- uniQure price target lowered to $46 from $53 at Guggenheim
- uniQure price target lowered to $14 from $24 at Wells Fargo
- uniQure price target lowered to $27 from $45 at Chardan
- uniQure selloff on AMT-130 update ‘appears overdone,’ says H.C. Wainwright